Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS Bends Knee Injection Code Policy Under Pressure From Genzyme

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency will pay for viscosupplement to treat osteoarthritic knees under four distinct codes, instead of lumping them into one as it had planned.

You may also be interested in...



Genzyme Next-Generation Osteoarthritis Candidate Hylastan Found Not Superior To Steroids

Failed therapy is now on the back burner, as focus turns to approval and introduction of single-treatment viscosupplementation product Synvisc-One, company tells “The Pink Sheet” DAILY.

Quality-Of-Life Data Favor Stenting Over Drugs In Short-Term

The high-profile COURAGE trial again raises the question of how soon stents should be placed in patients with coronary disease.

Topics

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel